Researchers reported at the 35th Congress of the European Society for Medical Oncology in Milan.

It binds collectively two existing cancer medications with the aim of delivering both medicines specifically to malignancy cells: trastuzumab, a monoclonal antibody that targets cells that overproduce the protein HER2; and DM1, a chemotherapy agent that targets microtubules. This is the first ever display of an anti-HER2 antibody-medication conjugate used as first-line therapy for individuals with advanced breast malignancy, said Professor Perez. We are encouraged by the outcomes. The analysis demonstrated that T-DM1 offers very good anti-tumor activity along with lower toxicity when evaluated side by side to the older ‘standard’. T-DM1 has shown promising activity in preclinical research.Headquartered in Staffordshire, UK, and with approved laboratories all over the world, Ceram solves product and process problems across a variety of materials to help clients improve performance, comply with regulations and develop their sustainability performance to be able to gain a competitive benefit and increase profitability. Ceram operates in a wide selection of sectors all over the world. To learn more visit.

Business of Wellness: Iowa companies merging, ‘quick’ growth for Mass. For-profit chain In Iowa, two non-profit nursing services are joining, and in Mass., Steward Health Care System’s growth is worrying community hospitals. Des Moines Register: Health non-profits HCI, Visiting Nurse Solutions Unite Two Iowa health care non-profits are joining forces as a way to climate cuts in Medicare and other programs.